Den 29 augusti offentliggjorde Nanologica att bolaget avser att genomföra en fullt garanterad företrädesemission av units om ca 99,4 MSEK. I intervjun berättar vd Andreas Bhagwani mer om emissionen och bakgrunden till den.
FINANCIAL SUMMARY Net sales for the second quarter amounted to SEK 2,174 thousand (672) and for the half-year to SEK 7,211 thousand (1,026) Operating loss for the quarter amounted to SEK -9,832 thousand (-13,312) and for the half-year to SEK -25,163 thousand (-24,032) Loss before tax for the quarter amounted to SEK -11,126 thousand (-14,671) and for the half-year to SEK -27,860 thousand (-26,764) Earnings per share before and after dilution were SEK -0.25 (-0.41)
We have now produced a number of consecutive large-scale batches within specifications which has enabled us to build up a stock of products for sale. We have also received our first slightly larger order for NLAB Saga® and we are now intensifying our sales efforts. It is very gratifying that the systematic work to further develop the large-scale production of our silica media NLAB Saga® has borne fruit – the plant now delivers significantly larger
Watch the presentation via the link: CEO Andreas Bhagwani presents at Redeye Diabetes Event – 23 May 2024
Nanologica’s CEO Andreas Bhagwani will present the company at Redeye Theme: Diabetes on 23 May at 11.10. Link to follow the event
